Gilead pays up to $3 billion for leg-up in CAR-T race

22 February 2018

In the latest multi-billion dollar deal in the fast-moving CAR-T space, US biotech giant Gilead Sciences (Nasdaq: GILD) has built on its $11.9 billion purchase of Kite Pharma by paying for its subsidiary to have exclusive access to Sangamo Therapeutics’ (Nasdaq: SGMO) gene-editing technology for the development of new ex vivo cell therapies in oncology.

Kite will use Sangamo’s zinc finger nuclease (ZFN) platform to modify genes to develop next-generation cell therapies for autologous and allogeneic use in treating different cancers.

"Allogeneic treatments can be accessed more conveniently in the hospital setting for people with cancer"

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK